Upcoming Global Web Symposia
August 19, 2010
11:30 am – 1:00 pm EST
The criteria for acceptable translational biomarkers and the various approaches to their selection will be discussed using real examples. In addition methods and requirements for qualification of translational biomarkers will be reviewed. The following areas will be highlighted:
Attendees will learn how to select appropriate biomarkers for use in preclinical models that will translate to humans. This will enable the translation of preclinical data into decision criteria for:
Instructor: Bruce H. Littman, M.D., former VP and Head of Translational Medicine at Pfizer, now President of Translational Medicine Associates, LLC
Who Should Attend:
Following post-graduate training as an internist, rheumatologist and immunologist at Tufts New England Medical Center, Harvard's Robert B. Brigham Hospital and the National Cancer Institute, N.I.H. in Bethesda, MD, and 13 years on the faculty of Virginia Commonwealth University’s Medical College of Virginia Bruce joined Pfizer's first Experimental Medicine group in 1989. His main focus became translational pharmacology, biomarker driven development decisions and exploratory clinical development across multiple therapeutic areas. He became the head of the Experimental Medicine group at legacy Pfizer with responsibility for research activities leading to proof of concept and was instrumental in starting Pfizer's Clinical Pharmacogenomics group and Pfizer's first biomarker laboratory. He played a key role in implementing important organizational changes through two major acquisitions. As Vice President, Global Head of Translational Medicine, he established Pfizer's Global Translational Medicine organization with groups in each of eleven therapeutic areas. Translational Medicine worked to improve the translatability of preclinical data into humans and increase Phase 2 survival through biomarker development for early validation of drug targets; demonstration of desired pharmacological activity in humans and development of clinical methods and biomarkers to advance the development of Pfizer products. In addition Bruce had other global development responsibilities including management of a large budget for biomarker qualification activities.
Bruce retired from Pfizer at the end of 2007 and started an independent consulting company, Translational Medicine Associates, LLC. He was also Co-Chair of the Inflammation and Immunity Steering Committee of The Biomarker Consortium (Foundation for the NIH) from 2007-2010 and has remained a member of that committee. He also serves on the Board of Directors of BioFortis, a small bioinformatics company. Over the last 1.5 years he has consulted extensively for large pharmaceutical and small biotech companies, non-profit research organizations and PhRMA.
250 First Avenue Suite 300Needham, MA 02494P: 781.972.5400F: 781.972.5425E: firstname.lastname@example.org
biological therapeutic productsbiomarkers & diagnosticsbiopharma strategybioprocess & manufacturingchemistryclinical trials & translational medicinedrug & device safety
drug discovery & developmentdrug targetsgenomicshealthcareit & informaticstechnology & tools for life sciencetherapeutic indications
conferencesReports & Market Researchbarnett educational servicesHealthtech PublishingKnowledge Foundation professional services
executive teamtestimonialschi timelinemailing listcareers